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Abstract
Background: There is limited data in Ghana on the epidemiology of HPV and cervical neoplasia and their
associations with HIV. This study aimed to compare among HIV-1 seropositive and HIV-seronegative Ghanaian
women: (1) the prevalence, genotype distribution and risk factors associated with cervical HPV infection; and (2) the
prevalence and risk factors associated with abnormal cervical cytology.
Methods: A comparative frequency-matched study was conducted in a systematic sample of women aged
≥18 years attending HIV and general outpatient clinics in Cape Coast Teaching Hospital, Ghana. Participants were
interviewed and cervical samples collected for HPV genotyping (Seegene Anyplex-II HPV28) and cytological testing.
Results: Overall, 333 women were recruited, 163 HIV-1 seropositive and 170 HIV-seronegative women of mean age
43.8 years (SD ±9.4)) and 44.3 years (SD ±12.8), respectively. The prevalence of 14 high-risk (hr) HPV genotypes was
higher among HIV-1 seropositive women (65.6% vs. 30.2%, P < 0.0001), as was proportion with multiple hr.-HPV
infections (60.6% vs. 21.3%, P < 0.0001). HPV35 was the most prevalent hr.-HPV genotype in both groups (11.9% and
5.3%). The main factors associated with hr.-HPV infection were age for HIV-positive women and circumcision status
of main sexual partner for both HIV-negative and positive women.
Abnormal cervical cytology prevalence was higher among HIV-1 seropositive women (any SIL: 14.1% vs. 1.2%, P < 0.
0001; low-grade SIL [LSIL]: 4.9% vs. 0.6%, P = 0.02; high-grade SIL: 1.8% vs. 0%, P = 0.07). Among HIV-1 seropositive
women, number of pregnancies and CD4+ cell count were associated with LSIL+ cytology. There was strong
association between LSIL+ abnormalities and HPV35 (aOR = 4.7, 95%CI: 1.3–17.7, P = 0.02).
Conclusions: HIV-1 infected women bear significant burden of HPV infection and related disease. Prevention and
screening programmes should be specifically deployed for this population in Ghana.
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Background
Persistent infection with genital human papillomavirus
(HPV) is causally linked with many genital cancers, in-
cluding cervical cancer [1, 2]. Genital HPV genotypes are
further categorized broadly into low-risk (lr) and high-risk
(hr) types based on their oncogenic potential. Persistence
of hr.-HPV in the transformation zone of about 10% of in-
fected persons may lead over time to squamous intrae-
pithelial lesions (SIL) or cervical intraepithelial neoplasia
(CIN) and invasive cervical carcinoma (ICC).
Co-infection with HPV has implications for HIV-infected
women and their health care providers. HIV increases the
risk of HPV persistence and development of associated cer-
vical lesions [3]. In particular, low CD4+ T-lymphocyte
counts may increase the risk of recurrence [4, 5], whilst
higher CD4+ cell counts may promote HPV clearance,
highlighting the role of immunity in the development of
cervical disease [6]. The role of antiretroviral therapy (ART)
is more complex. By decreasing HIV plasma viral load and
restoring immunity, ART is expected to have benefits in re-
ducing HPV-associated clinical conditions among HIV-
infected women [7–9], especially among ART users with
high adherence [10]. However, several studies have not re-
ported such benefits of ART directly [11–13]. Improved
survival among women living with HIV taking ART in-
creases potential exposure time and may lead to higher
cancer rates, underscoring the need for specific screening
and management programmes in this high-risk population.
Other known risk factors of HPV acquisition, persistence
and development of cervical lesions include age, age at first
sexual activity, life time number of sexual partners [14–16],
smoking [17], hormonal contraceptive use [18, 19], co-
infection with other STIs [20, 21] and lack of circumcision
of the male partner [22].
Forman et al. [23] have estimated the global adjusted
HPV prevalence to be 11.7%, with West Africa having the
fourth highest with a prevalence of 19.6%. Limited data on
HPV and SIL/CIN epidemiology are available in Ghana
from women attending gynaecological clinics. Brandful et
al. [24] reported an HPV prevalence of 64.5% among HIV-
seronegative pregnant women in Accra. Attoh et al. [25] in
their study among 50 women diagnosed with cervical can-
cer in Ghana found cervical HPV DNA prevalence of 98%,
with HPV18 being the most predominant type (84%)
followed by HPV16 (24%). Cervical cancer screening in the
country is not systematically organized with some pilot im-
plementation of the WHO-recommended visual inspection
with acetic acid (VIA) [26], whilst cytological screening
using the Papanicolaou (pap) method is becoming more
available, albeit with associated significant costs and logis-
tical challenges.
Since 2005, the use of HPV vaccines, first the bivalent
and quadrivalent vaccines targeting HPV16 and 18 linked
to 70% of invasive cancers (and low risk HPV 6 and 11),
and recently the nonavalent vaccine targeting the same
types plus five other hr. types (HPV31, 33, 45, 52 and 58),
globally linked to 90% of cancers [27], has made primary
prevention possible. These vaccines have been shown to
be effective in preventing HPV infection and the
development of genotype-specific HPV-associated clinical
conditions [28–30]. In Ghana, a pilot HPV vaccination
programme targeting school-going girls aged 9–13 was
carried out in 2013 in selected regions using the quadriva-
lent vaccine. More detailed information on the prevalence
and distribution of HPV genotypes associated with lesions
in various patient groups in Ghana would help inform
HPV vaccination and screening plans.
The objectives of this study were to compare between
HIV-1 sero-positive and HIV sero-negative women in
the Cape Coast Metropolis of Ghana: (1) the prevalence,
genotype distribution and risk factors associated with
HPV infection, and (2) the prevalence and risk factors
associated with abnormal cervical cytology (ASCUS+).
Methods
Study design and subjects
This study was a comparative frequency-matched study
conducted among women ≥18 years attending the HIV or
medical outpatient clinic of the Cape Coast Teaching
Hospital (CCTH) in Ghana. A systematic sampling of
every 5th woman was used starting with a random sam-
pling of the first woman. Women who were ineligible
(previous total hysterectomy, pregnant or menstruating
on that day), had the opportunity passed on to the next
until a total of 10 women per day were selected. After re-
cruitment, the study protocol was explained to each
woman and written informed consent was then obtained.
Enrolled women then had their HIV status confirmed
and then they answered a questionnaire in either English
or the local language (Fante). This questionnaire gath-
ered socio demographic characteristics of the women
and then for HIV positive women, the HIV specific char-
acteristics including use of ART, nadir CD4+ T-
lymphocytes count, and WHO clinical staging were also
obtained (Additional file 1).
Sample collection
Blood was drawn to perform HIV serology using the First
Response Kit (Premier Medical Corporation Limited, India)
to detect HIV-1 and HIV-2 antibodies, confirmed with the
OraQuick kit (OraSure Technologies, USA), as per national
guidelines. Counseling based on the results was done for all
women and women found HIV-1 seropositive but not
already in care were referred to the ART treatment center
at CCTH. Participants underwent gynaecological examin-
ation with speculum, during which cervical swabs were
collected from the ecto/endocervix targeting the squamo-
columnar junction using a DNA PAP™ Cervical Sampler™
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and transported in the Swab Specimen Collection Kit (Qia-
gen, Gaithersburg, MD). Cervical smears were taken for cy-
tology with a cervical brush and alcohol-fixed at the clinic.
All women found to have LSIL+ cytology were referred to
the gynaecologist for further evaluation and management.
HPV DNA detection
HPV genotyping was performed using the recently devel-
oped Anyplex™ II HPV28 assay (Seegene, Seoul, Korea).
The assay detects 28 HPV genotypes including 19 h-HPV
types, of which 13 are considered carcinogenic (HPV16, 18,
31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 68) and 6 possible car-
cinogenic (HPV26, 53, 66, 69, 73, 82), and 9 low-risk HPV
types (HPV6, 11, 40, 42, 43, 44, 54, 61, 70), according to the
Interagency for Research on Cancer (IARC) [31]. This assay
has been compared with the Digene HC2 HPV DNA assay
(Qiagen) and found to be analytically more sensitive in de-
tecting the 13 h-HPV types identifiable by both assays, in
addition to having higher concordance with comprehensive
genotyping based on sequencing analysis [32].
The isolation of nucleic acid was done by QIAamp
DNA Mini kit (Qiagen, USA) following manufacturer’s
instructions. Extracted DNA samples were aliquoted and
stored at -20 °C. The next step was the multiplex real
time PCR using the Anyplex™ II HPV28 (Seegene,
Korea) following manufacturer’s protocol with the
CFX96™ Real-time PCR System (Bio-Rad, USA). In brief,
this involved preparation of a master mix which con-
tained RNAase free water (5 μl per sample), 4X Anyplex
solution (5 μl per sample) and 4X HPV28 TOM A or
TOM B solutions (5 μl per sample for each type). TOM
A contained the primers for hr.-HPV genotypes, while
TOM B contained primers for non hr.-HPV types. Both
reactions were set up to run concurrently. To 15 μl of
reagents was added 5 μl of the prepared DNA sample.
A set of 3 external positive controls and a negative con-
trol were included in each set to run with the samples. To
be valid for any sample, both the internal and external
controls must have expected result. When the external
controls failed the whole set was invalid and no results
were read. When the internal control for a sample failed,
whilst all external controls were correct, that particular
sample result was considered invalid and it tested again.
Cervical cytology
Following a standardized protocol for Papanicolaou (pap)
staining, cervical smears were prepared in the laboratory
and read by a consultant cytopathologist at CCTH using the
Bethesda 2001 guidelines and the LASTguidelines [33, 34].
Sample size and statistical analysis
Sample size was calculated to allow comparisons of HIV-1
seropositive and HIV-seronegative women. Assumptions
on HPV and cytological abnormality prevalence in each
group were based on findings from different studies
around the Africa region and sample size was powered to
detect differences in the lowest frequency outcome (cyto-
logical abnormalities). Data analyses were performed using
Stata version 13 software (STATA Corp, Texas USA).
A descriptive analysis of socio-demographic, behaviour
and other relevant characteristics of the study population
was done according to HIV serostatus. P-values were used
to compare the parameters between the groups based on
student’s t-test for continuous variables or chi- square test
for categorical variables. Bivariate analysis was done separ-
ately for the two study outcomes (HPV and cytological ab-
normalities) stratified by HIV serostatus.
Based on outcome frequency, associations are presented
as prevalence or risk ratios (PR/RR) with 95% confidence
intervals (CI) for the HPV outcomes, and odds ratios
(OR) and 95%CI for the cytological abnormality outcomes.
Variables with P-values ≤0.20 and a priori factors like age
were put in the model for multivariate analysis.
Results
Study participants
A total of 333 (163 HIV-1 seropositive and 170 HIV-
seronegative) women were recruited between July and De-
cember 2014. Participant characteristics are shown in
Table 1. The mean age of participants was 43.8 (SD ±9.4)
years for HIV-1-seropositive women and 44.3 years (SD
±12.8) for HIV-seronegative women. Compared to HIV-
seronegative women, HIV-1 seropositive women were less
educated, more frequently in unskilled occupations, without
a current partner but with a larger number of lifetime part-
ners. Smoking was rare in this population (about 2% overall)
and hormonal contraceptive history infrequent (39.3% and
42.4%, in HIV-1 seropositive and HIV-seronegative women,
respectively). Most male sexual partners (93%) were circum-
cised, as expected in Ghana (Table 1).
The majority (57.1%) of HIV-1 seropositive participants
had been diagnosed with HIV less than 5 years ago with a
median duration since HIV diagnosis of 4.3 years (inter-
quartile range [IQR], 1.9–7.1). Most (79.1%) were taking
ART, 62% for longer than 2 years. The median nadir CD4
+ count of women on ART and ART-naïve was 202 cells/
mm3 (IQR, 96–289) and 460 cells/mm3 (IQR, 378–560),
respectively (Table 2).
Prevalence of HPV, genotype distribution and risk factors
for hr.-HPV
A total of 329/331 obtained samples were successfully ge-
notyped using the Seegene Anyplex II HPV28 protocol,
with two samples (0.6%) giving invalid results. The overall
HPV DNA prevalence was 75% (120/160) among HIV-1
seropositive women and 42.6% (72/169) among HIV-
seronegative women (p < 0.0001). Compared to HIV-
seronegative women, HIV-1 seropositive women had a
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Table 1 Characteristics and laboratory findings of enrolled participants in Cape Coast, Ghana
VARIABLES HIV-1 seropositive (N = 163) HIV seronegative (N = 170) P-value
n (%), or mean/median (SD or IQR) n (%), or mean/median (SD or IQR)
Age, years 0.03
Mean (SD) 43.8 (9.4) 44.3 (12.8)
≤ 29 11 (6.8) 21 (12.4)
30–59 142 (87.1) 129 (75.9)
> 60 10 (6.1) 20 (11.8)
Marital status <0.0001
Currently with a regular sexual partner 70 (42.9) 126 (74.1)
Currently without a regular sexual partner 93 (57.1) 44 (25.9)
Education <0.0001
No formal education 40 (24.5) 28 (16.5)
Up to secondary school level 117 (71.8) 75 (44.1)
Tertiary level 6 (3.7) 67 (39.4)
Employment <0.0001
Unemployed 14 (8.6) 14 (8.2)
Unskilled occupation 137 (84.1) 89 (52.4)
Skilled occupation 12 (7.4) 67 (39.4)
Age at first sex, years Categorical 0.16
Median (IQR) 18 (17–20) 19 (18–21)
≤ 15 7 (4.3) 6 (3.5)
16–20 127 (77.9) 119 (70.0)
≥ 21 29 (17.8) 45 (26.5)
Lifetime no. sexual partners 0.004
Median 3 (2–4) 3 (2–3)
1 11 (6.8) 31 (18.2)
2–5 139 (85.3) 131 (77.1)
> 5 13 (8.0) 8 (4.7)
Circumcision main/current partner 0.90
Circumcised 153 (93.9) 159 (93.5)
Not circumcised 10 (6.1) 11 (6.5)
Smoking 0.09
Ever/Current 5 (3.1) 1 (0.6)
Never smoked 158 (96.9) 169 (99.4)
Hormonal contraception 0.57
Ever/Current 64 (39.3) 72 (42.4)
Never used 99 (60.7) 98 (57.6)
Cytology <0.0001
Normal 140 (85.9) 168 (98.8) <0.0001
ASCUS 12 (7.4) 1 (0.6) 0.001
LSIL 8 (4.9) 1 (0.6) 0.02
HSIL/ASC-H 3 (1.8) 0 (0) 0.07
HPV DNA 120/160 (75.0) 72/169 (42.6) <0.0001
SD Standard Deviation, IQR Interquartile Range, ASCUS Atypical Squamous Cells of Undetermined Significance, LSIL Low Grade Squamous Intraepithelial Lesions,
HSIL High Grade Squamous Intraepithelial Lesions, ASC-H atypical squamous cells cannot rule out HSIL
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higher prevalence of hr.-HPV genotypes (65.6% vs. 30.2%,
P < 0.0001), multiple HPV infections (60.6% vs. 21.3%,
P < 0.0001), HPV16 and/or 18 infection (21.3% vs. 2.4%,
P < 0.0001), or infection with hr.-HPV types included in
the nonavalent vaccine (i.e. HPV16/18/31/33/45/52/58/6/
11) (55.6% vs. 17.2%, P < 0.0001) (Table 3). The most preva-
lent hr.-HPV genotypes among HIV-1 seropositive women
in this study were HPV35 (11.9%), 52 (11.9%), 58 (11.3%),
16 (10.6%) and 18 (10.6%), whereas among HIV-negative
women the most prevalent types were HPV35 (5.3%), 58
(4.1%), 33 (4.1%), 56 (3.6%), and 52 (2.4%) (Table 3).
Overall, hr.-HPV prevalence was strongly associated
with HIV-1 serostatus (PR = 2.2, 95%CI: 1.7–2.8). Table 4
show details of the bivariate analyses for hr.-HPV infec-
tion. Among HIV-1 seropositive women the main risk
factor for hr.-HPV was age and male partner’s lack of
circumcision; among HIV-seronegative women, the main
risk factor was the male partner’s lack of circumcision
(RR = 1.9, 95% CI: 1.1–3.5, P = 0.03), Table 4.
Prevalence of, and risk factors associated with abnormal
cytology
The distribution of cytological results by HIV serostatus is
shown in Table 1. The prevalence of abnormal cytology
was higher among HIV-1 seropositive women (any SIL:
14.1% vs. 1.2%, P < 0.0001; low-grade SIL [LSIL]: 4.9% vs.
0.6%, P = 0.02; high-grade SIL [HSIL]: 1.8% vs. 0%,
P = 0.07). HPV35 was the most frequent hr.-HPV type as-
sociated with LSIL and above (LSIL+) (Fig. 1).
Among HIV-1 seropositive women, having more than
4 pregnancies increased the risk of having LSIL+ abnor-
malities (aOR = 4.1, 95% CI: 1.1–17.0), while CD4+
count >350 cells/mm3 decreased the risk (aOR = 0.3,
95%CI: 0.07–0.9) (Table 5). HPV35 was the type most
strongly associated with LSIL+, adjusting for age and
HIV status (aOR = 4.7, 95% CI: 1.3–17.7, P = 0.02).
There were too few HIV-seronegative women with SIL
to conduct any meaningful risk factor analysis.
Discussion
This study reports for the first time the comparative preva-
lence and genotype distribution of HPV among HIV-1 sero-
positive and seronegative women in Ghana. Findings from
research conducted mainly in developed countries and few
Table 2 Clinical characteristics of 163 HIV-1 seropositive women
at enrolment
VARIABLES n (%) or median (IQR)
Duration of HIV diagnosis, years (N = 163)
Median 4.3 (1.9–7.0)
< 5 93 (57.1)
≥ 5 70 (42.9)
ART status (N = 163)
Not on ART 34 (20.9)
≤ 2 years 28 (17.1)
> 2 years on ART 101 (62.0)
WHO clinical stage (N = 159)
Stage I & II 80 (50.3)
Stage III & IV 79 (49.7)
Nadir CD4+ count, cells/mm3 (N = 155)
Median 246 (125–398)
< 200 63 (40.7)
200–349 49 (31.6)
350–500 22 (14.2)
> 500 21 (13.6)
ART antiretroviral therapy, IQR interquartile range
Table 3 HPV prevalence and genotype distribution among
HIV-1 seropositive and HIV-seronegative women in Cape
Coast, Ghana
HPV genotypes HIV-1 positive
(N = 160)
HIV negative
(N = 169)
P-value
n (%) n (%)
HPV 16 17 (10.6) 1 (0.6) <0.0001
HPV 18 17 (10.6) 3 (1.8) 0.001
HPV 31 13 (8.1) 1 (0.6) 0.001
HPV 33 8 (5.0) 7 (4.1) 0.71
HPV 35 19 (11.9) 9 (5.3) 0.03
HPV 39 7 (4.4) 3 (1.8) 0.17
HPV 45 10 (6.3) 2 (1.2) 0.01
HPV 51 2 (1.3) 0 (0.0) 0.14
HPV 52 19 (11.9) 4 (2.4) 0.001
HPV 56 13 (8.1) 6 (3.6) 0.07
HPV 58 18 (11.3) 7 (4.1) 0.01
HPV 59 8 (5.0) 2 (1.2) 0.04
HPV 68 15 (9.4) 3 (1.8) 0.002
Any HPV 120 (75.0) 72 (42.6) <0.0001
Any hr.-HPV 105 (65.6) 51 (30.2) <0.0001
HPV 16/18 (bivalent
vaccine types)
34 (21.3) 4 (2.4) <0.0001
HPV 16/18/6/11 (quadrivalent
vaccine types)
53 (33.1) 7 (4.1) <0.0001
HPV 16/18/31/33/45/52/58/6/11
(nonavalent vaccine types)
89 (55.6) 29 (17.2) <0.0001
Low risk types only 15 (9.4) 21 (12.4) 0.38
HPV 6 12 (7.5) 1 (0.6) 0.001
HPV 11 10 (6.3) 2 (1.2) 0.01
HPV 6 and/or 11 21 (13.1) 3 (1.8) <0.0001
Multiple types
2–5 64 (52.5) 36 (21.3) <0.0001
> 5 13 (8.1) 0 (0.0) <0.0001
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studies across Africa have shown a higher prevalence of
HPV infection (any HPV, hr.-HPV, multiple HPV) among
HIV-1-seropositive compared with HIV-seronegative
women [7, 35–37]. In Ghana as elsewhere, HIV-1 seroposi-
tive women were significantly more frequently infected with
HPV, and twice more likely to have high-risk and multiple
HPV genotypes. The absolute hr.-HPV prevalence among
HIV-1 seropositive women (66.8%) is much higher than
that reported by Ezechi et al. [36] in a study conducted
among 220 HIV-1 seropositive and 295 HIV-seronegative
women in Nigeria, which reported hr.-HPV prevalence of
24.6% and 15.9% in the respective groups. Another study in
South Africa reported a twice higher prevalence of any hr.-
HPV infection among 145 HIV-1 seropositive and 107
HIV-seronegative women (68% versus 31%) [38], which is
comparable to this study. Some of the differences in preva-
lence may be attributable to the HPV detection assay used
[39], with genotyping assays such as the Anyplex-II HPV
28 used in this study more likely to have higher sensitivity.
In addition, the population in this study had relatively low
nadir CD4+ count (<350 cells/mm3) and a worse WHO
HIV/AIDS score III/IV (50%) hence more likely to have
higher HPV prevalence.
HPV genotype prevalence and associated risk factors
Since protection afforded by HPV vaccines is essentially
type specific [40, 41], knowledge of the genotype
distribution in a specific population has implications for
vaccine choice and predicted impact. The most prevalent
hr.-HPV type in both groups in this study was HPV35,
which none of the available vaccines on the market
includes. The quadrivalent HPV vaccine is used in
most countries and covers for only HPV6, 11, 16 and
18 [42, 43]. The recent introduction of the nonavalent
vaccine to cover for additional HPV31, 33, 45, 52 and
58 may lead to a change in vaccine choice among
countries and countries yet to implement wide scale
or routine vaccination programs including Ghana.
HPV16 and 18 are said to contribute to about 70%
of cervical cancer cases [44] and this has influenced
vaccine development. This study demonstrated the as-
sociation between HPV35 and abnormal cytology in
Ghana. A study in neighbouring Burkina Faso found
HPV35 to be the second most prevalent among sex
workers with high prevalence of HIV [37]. Another
study conducted in South Africa reported HPV35 as
the third most prevalent genotype identified among
154 HIV-seronegative women with ICC [45]. Pirek et
al. [46] found HPV35 the fifth commonest among
Cameroonian women with ICC and HPV45 was the
second most prevalent type. Maranga et al. [47] in
their study among Kenyan women also found that
HPV45 contributed significantly to cervical cancer
among HIV-seropositive women. Attoh et al., [25] in
Table 4 Factors associated with hr.-HPV infection in bivariate analyses, stratified by HIV serostatus
VARIABLES HIV-1 seropositive women HIV seronegative women
hr-HPV (N = 105) n (%) RR (95% CI) P-value hr-HPV (N = 51) n (%) RR (95% CI) P-value
Age, years
≤ 29 10 (90.9) 1 6 (30.0) 1
30–59 89 (64.0) 0.6 (0.5–0.7) <0.0001 38 (29.5) 1.1 (0.5–2.1) 0.94
> 60 6 (60.0) 0.5 (0.3–0.9) 0.02 7 (35.0) 1.2 (0.5–3.2) 0.64
Age at first sex, years categorical
≤ 18 48 (57.8) 1 22 (29.3) 1
> 18 57 (74.0) 1.3 (1.1–1.6) 0.03 29 (30.9) 1.1 (0.7–1.7) 0.83
Lifetime number of sexual partners
1 9 (81.8) 1 8 (25.8) 1
≥ 2 96 (64.4) 0.9 (0.6–1.2) 0.49 43 (31.2) 1.2 (0.6–2.3) 0.57
Circumcision status of main/current partner
Circumcised 97 (64.7) 1 45 (28.5) 1
Not circumcised 8 (80.0) 1.4 (1.2–1.6) <0.0001 6 (54.6) 1.9 (1.1–3.5) 0.03
Smoking history
Never smoked 101 (65.2) 1 50 (29.9) 1
Smokers (Ex/current) 4 (80.0) 1.2 (0.8–1.9) 0.38 1 (50.0) 1.7 (0.9–3.8) 0.47
Hormonal contraceptive history
Ever used 40 (63.5) 1 23 (32.4) 1
Never used 65 (67.0) 1.1 (0.8–1.3) 0.66 28 (28.6) 0.9 (0.6–1.4) 0.63
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their study among Ghanaian women with cervical
cancer detected 8 h-HPV genotypes (16, 18, 35, 39,
45, 52, 56 and 66) with HPV18 being the most preva-
lent. Another study based in sub-Saharan Africa with
inclusion of samples from Ghana found that HPV
type distribution appeared to differ according to
tumor type and HIV status and HPV16, 18, 45 and
35 were the most common HPV types in women with
ICC [48]. In this study, hr.-HPV types included in the
bi- or quadrivalent vaccines (HPV16/18) and nonava-
lent vaccine (HPV16/18/31/33/45/52 and 48) were
found in higher proportions among HIV-1 seroposi-
tive compared with HIV-seronegative women.
Among study participants, there was evidence of an
association between having hr.-HPV infection and youn-
ger age among HIV positive participants and lack of cir-
cumcision of the male partner among both HIV positive
and negative groups. These findings are consistent with
existing literature [49, 50]. Other studies in Ghana and
other parts of the world have reported association be-
tween employment status, marital status and educational
level with HPV [51, 52].
Fig. 1 High-risk HPV genotypes prevalence by cytological category, for HIV-1 seropositive women (N = 163). Figure legend: ASCUS = Atypical Squamous
Cells of Undetermined Significance, LSIL = Low Grade Squamous Intraepithelial Lesions, HSIL = High Grade Squamous Intraepithelial Lesions
Table 5 Bivariate and multivariate analyses of low-grade squamous intraepithelial lesions and higher (LSIL+) among HIV-1
seropositive women in Cape Coast, Ghana
VARIABLES LSIL+, n (%) OR (95% CI) P-value aAOR (95% CI) P-value
Age, years
≤ 44 7 (7.9) 1 0.5 (0.1–1.8) 0.34
≥ 45 4 (5.4) 0.6 (0.2–2.4) 0.53
Education
≤ 6 years of formal education 7 (9.7) 1 0.5 (0.2–1.9) 0.30
> 6 years of formal education 4 (4.4) 0.4 (0.1–1.5) 0.18
Employment
Unemployed 2 (14.3) 1
Employed 9 (6.0) 0.4 (0.1–2.0) 0.24
Smoking history
Never smoked 10 (6.3) 1
Smokers (Ex/current) 1 (20.0) 3.7 (1.4–16.9) 0.23
Number of pregnancies
≤ 4 3 (3.3) 1 4.1 (1.1–17.0) 0.05
> 4 8 (11.1) 3.7 (0.9–14.7) 0.05
Nadir CD4+ count, cells/mm3
≤ 350 10 (8.9) 1 0.3 (0.07–0.9) 0.04
> 350 1 (2.3) 0.2 (0.03–2.0) 0.15
aadjusted for age, level of education, total number of pregnancies and nadir CD4 count
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Epidemiology of cytological abnormalities and associated
risk factors
Compared with HIV-seronegative women, HIV-1 sero-
positive women in this study had a higher prevalence of
SIL and higher grade cytological lesions. Indeed, HSIL/
ASC-H were only identified among HIV-1 seropositive
women. A study conducted among women in selected
communities in the Ashanti region of Ghana found any
SIL prevalence ranging between 3.5% and 12.6% [53], al-
though this study did not report HIV status. Elsewhere in
sub-Saharan Africa, Hood et al. reported that cervical le-
sions were significantly associated with the detection of
plasma HIV RNA (with an adjusted relative risk of 1.16,
95% CI: 1.05–1.28) among women in Senegal [54]. An-
other study in Kenya among 267 HIV-seropositive women
on ART found a much higher prevalence of abnormal cy-
tology of 46%. The median duration of antiretroviral ther-
apy was 13 months (IQR: 8–19) [55]. In another study
conducted in South Africa among 109 HIV-seropositive
women before initiation of ART, the prevalence of abnor-
mal cytology was 66.3%. The median CD4 count among
these women was very low at 125 cells/mm3 [56].
In the sub-group analysis for HIV-1 seropositive
women, factors which showed strong evidence of an as-
sociation with SIL included nadir CD4+ T-cell count. A
higher CD4+ T-cell count reflects a stronger immune
system, which may be associated with greater ability to
clear HPV infection compared with women who ac-
quire HPV whilst more seriously immunocompromised,
which may lead to more frequent persistence and a
greater chance to develop lesions. The association with
nadir CD4+ T-cell count has been demonstrated in
other studies [5, 6, 36]. This study had some limita-
tions. It was facility-based, which allowed for more con-
venience in recruitment, but its results may not be
generalizable. Histology confirmation of lesions would
have also been preferable as it is more specific diagno-
sis than cytology, although this has been a usual limita-
tion of several epidemiological studies in sub-Saharan
Africa. An important limitation is the unavailability of
current HIV viral load and CD4 count for the HIV
positive participants. Nonetheless, this study brings
useful information for decision makers in the country,
demonstrating that the burden of HPV infection and
hr.-HPV infection is high in Ghana. The study also
showed that the most prevalent HPV genotype was
HPV35, and that among HIV-seronegative women,
HPV16 and 18 were not among the top five most
prevalent genotypes. The established contribution from
HPV 16 and 18 has appropriately informed vaccine
choices, nevertheless, the genotype distribution pattern
found in this and other studies imply the need to look
carefully at vaccine choices for primary prevention of
HPV and cervical cancer among women in Ghana.
Conclusion
The study shows the need for a systematic national cer-
vical cancer screening program in view of the high HPV
prevalence even among the HIV seronegative women.
This may include scheduled screening for women in
Ghana using Pap smear, visual inspection (VIA) and the
possibility of HPV screening. For HIV positive women,
screening using HPV testing may be challenging since
over 50% of them may be positive. Strong cervical can-
cer prevention and screening programs should be specif-
ically deployed targeting HIV-seropositive women in
Ghana. In addition, it demonstrates that prophylactic
vaccination of young girls with the nonavalent HPV vac-
cine is likely the best means of cervical cancer preven-
tion in Ghana.
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